RTI-55

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by David Hedlund (talk | contribs) at 16:52, 5 February 2013 (→‎References). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

RTI-55
Clinical data
Other names(–)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane; β-CIT
Legal status
Legal status
Identifiers
  • Methyl (1R,2S,3S)-3-(4-iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
CAS Number
PubChem CID
Chemical and physical data
FormulaC16H20INO2
Molar mass385.24 g/mol g·mol−1
3D model (JSmol)
  • CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC
  (verify)

RTI-55 (iometopane) is a phenyltropane-based psychostimulant used in scientific research and with some medical application/s. This drug was first cited in 1991.[1] RTI-55 is a non-selective dopamine reuptake inhibitor derived from methylecgonidine. However, more selective analogs are derived by conversion to "pyrrolidinoamido" RTI-229, for instance. Due to the large bulbous nature of the weakly electron withdrawing iodo halogen atom, RTI-55 is the most strongly serotonergic of the simple para-substituted troparil based analogs.[2] In rodents RTI-55 actually caused death at a dosage of 100 mg/kg, whereas RTI-51 and RTI-31 did not.[2] Another notable observation is the strong propensity of RTI-55 to cause locomotor activity enhancements,[2] although in an earlier study, RTI-51 was actually even stronger than RTI-55 in shifting baseline LMA.[3] This observation serves to highlight the disparities that can arise between studies.

RTI-55 is one of the most potent phenyltropane stimulants commercially available, which limits its use in humans, as it might have significant abuse potential if used outside of a strictly controlled medical setting.[4] However, it is definitely worthy of mentioning that increasing the size of the halogen atom attached to troparil serves to reduce the number of lever responses in a session when these analogs were compared in a study.[5] Although RTI-55 wasn't specifically examined in this study the number of lever responses in a given session was of the order cocaine > WIN35428 > RTI-31 > RTI-51.

In contrast to RTI-31 which is predominantly dopaminergic, increasing the size of the covalently bonded halogen from a chlorine to an iodine markedly increases the affinity for the SERT, while retaining mostly all of its DAT blocking activity.

If desired, a radioactive source of iodine can be utilized.

I123 and I125 in particular because these are very high energy γ-ray emitters.

Compared to the "WIN" compounds, extremely low Ki values are attainable.

Uses

RTI-55 is mainly used in scientific research into the dopamine reuptake transporter. Various radiolabelled forms of RTI-55 (with different radioactive isotopes of iodine used depending on the application) are used in both humans and animals to map the distribution of dopamine transporters and serotonin transporters in the brain.[6][7] The 123I derivative is known as iometopane.

The main practical application for this drug in medicine is to assess the rate of dopamine neuron degradation in the brains of sufferers of PD,[8][9] and some other conditions such as progressive supranuclear palsy.[10]

Chemistry

RTI-55 is made as follows:[11][12][13]

See also

References

  1. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 2060590, please use {{cite journal}} with |pmid=2060590 instead.
  2. ^ a b c Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15566309, please use {{cite journal}} with |pmid=15566309 instead.
  3. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11714587, please use {{cite journal}} with |pmid=11714587 instead.
  4. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7675883, please use {{cite journal}} with |pmid=7675883 instead.
  5. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15957006, please use {{cite journal}} with |pmid=15957006 instead.
  6. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 1585258, please use {{cite journal}} with |pmid=1585258 instead.
  7. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17224717, please use {{cite journal}} with |pmid=17224717 instead.
  8. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 10874697, please use {{cite journal}} with |pmid=10874697 instead.
  9. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17504864, please use {{cite journal}} with |pmid=17504864 instead.
  10. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16908744, please use {{cite journal}} with |pmid=16908744 instead.
  11. ^ U.S. patent 5,128,118
  12. ^ U.S. patent 6,123,917
  13. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 8589674, please use {{cite journal}} with |pmid=8589674 instead.
Retrieved from "https://en.wikipedia.org/w/index.php?title=RTI-55&oldid=536718606"